Related Experiment Videos
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment
E Petroske1, G E Meredith, S Callen
1Division of Pharmacology, School of Pharmacy, University of Missouri-Kansas City, 64108, USA.
Abstract:
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is widely used to induce an animal model of Parkinsonism. The conventional mouse model, which usually involves acute or subacute injections of MPTP, results in a significant but reversible loss of dopaminergic functions. We have developed an alternative mouse model, in which co-administration of MPTP with probenecid results in the chronic loss of striatal dopamine for at least 6 months after cessation of treatment. In the present study, we compare the neurochemical, morphological and behavioral changes that occur in this alternative, chronic model with those in the conventional, subacute model. In the chronic model, we demonstrate an almost 80% loss of striatal dopamine and dopamine uptake 6 months after withdrawal from treatment. The neurochemical signs match unbiased stereological measures that demonstrate gradual loss of substantia nigra neurons. Rotarod performance further substantiates these findings by showing a progressive decline in motor performance. Based on the comparisons made in this study in mice, the chronic MPTP/probenecid model shows considerable improvements over the conventional, subacute MPTP model. The sustained alterations in the nigrostriatal pathway resemble the cardinal signs of human Parkinson's disease and suggest that this chronic mouse model is potentially useful to study the pathophysiology and mechanisms of Parkinsonism. It should also prove useful for the development of neuroprotection strategies.
Insights
A new chronic mouse model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and probenecid causes sustained Parkinsonism-like changes. This model offers a more robust platform for studying Parkinson's disease mechanisms and testing neuroprotective strategies.
Area of Science:
- Neuroscience
- Pharmacology
- Animal Models
Background:
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a common agent for creating animal models of Parkinsonism.
- Conventional MPTP models often exhibit transient dopaminergic deficits, limiting their utility for studying chronic Parkinson's disease progression.
Purpose of the Study:
- To compare a novel chronic MPTP/probenecid mouse model with the conventional subacute MPTP model.
- To evaluate the long-term neurochemical, morphological, and behavioral effects of chronic MPTP/probenecid administration.
Main Methods:
- Administration of MPTP with probenecid to induce chronic Parkinsonism in mice.
- Assessment of striatal dopamine and dopamine uptake levels.
- Unbiased stereological analysis of substantia nigra neuron loss.
- Evaluation of motor performance using Rotarod tests.
Main Results:
- The chronic MPTP/probenecid model demonstrated an ~80% loss of striatal dopamine and uptake 6 months post-treatment.
- Significant, progressive loss of substantia nigra neurons was observed.
- Progressive motor deficits were evident in Rotarod performance tests.
Conclusions:
- The chronic MPTP/probenecid mouse model exhibits sustained nigrostriatal pathway alterations mimicking human Parkinson's disease.
- This model provides a valuable tool for investigating Parkinson's pathophysiology and developing neuroprotection strategies.
- The chronic model offers significant advantages over conventional subacute MPTP models for Parkinson's disease research.